Navigation Links
Liver transplant recipients have higher cancer risk
Date:11/3/2008

A new Canadian study comparing cancer rates of liver transplant patients to those of the general population has found that transplant recipients face increased risks of developing cancer, especially non-Hodgkin's lymphoma and colorectal cancer. Risks were more pronounced during the first year of follow-up and among younger transplant recipients. These findings are published in the November issue of Liver Transplantation, a journal by John Wiley & Sons. The article is also available online at Wiley Interscience (www.interscience.wiley.com).

Transplantation, and the immunosuppressants which keep the body from rejecting the new organ, have been shown to increase a patient's cancer risk. However, most studies that have considered the issue have been limited by data from a single center, or by small numbers of patients.

In a new population-based cohort study, researchers led by Ying Jiang of the Public Health Agency of Canada used the Canadian Organ Replacement Registry to gather information on all liver transplant recipients and cross-reference them with national mortality and cancer incidence databases.

The researchers included 2,034 patients who received a transplant between June 1983 and October 1998, and followed them for up to 15 years. They excluded patients who had liver cancer or who had been diagnosed with any other type of cancer (except for non-melanoma skin cancer) before transplantation, or in the 30 days immediately afterwards.

After 10,370.6 person-years of follow-up, the group of transplant recipients developed 113 cancers (not including liver cancer), compared to the 44.8 cases that were expected based on rates in the general population. The standardized incidence ratio (SIR) for all cancers was 2.5 relative to the overall Canadian population. "This ratio appears to be a lower estimate when compared with the existing literature," the authors report, possibly
'/>"/>

Contact: Sean Wagner
swagner@wiley.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Mayo Clinics new imaging technology accurately identifies a broad spectrum of liver disease
2. New Imaging Identifies Types of Liver Disease
3. How did glycine significantly decrease liver injury?
4. New Analyses Confirm Nexavars Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
5. International Medical Corps Continues Delivering Emergency Relief Amid Violence in Democratic Republic of Congo
6. Patient Placement Systems Selects Iatric Systems, Inc. to Deliver Interfaces for MEDITECH Healthcare Information Systems
7. New study indicates that exercise prevents fatty liver disease
8. Vaginal/Caesarean combo delivery of twins safe, UT Southwestern-led research finds
9. Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award
10. No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults
11. PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)..., , SOUTHBRIDGE, Mass., Dec. 3 /PRNewswire/... approval to treat its first patients, Harrington ...t seeing patients immediately," said Diane Becquar..., The approval was granted today by the Massachu...ty and quality review of the facility. ,, The ...
(Date:12/3/2009)..., , BEIJING, Dec. 3 /PRNewswire-Asia/...enefits, ginger, one of the most important ingredi...in China during this flu season. , The ti... supply shortages,effecting upward price pressure...potential repeat of the current demand hysteria ov...
(Date:12/3/2009)..., , SILVER SPRING, Md., Dec. 3 /PRNewsw...g a health care system that ensures affordable, qu...on urges all Americans to contact their representa...h care reform. ,, See video from ANA at: http:...dvocating for a health care system that focuses on...
(Date:12/3/2009)...Roles of aggressor, victim often play out at schoo...c. 3 (HealthDay News) -- School bullies are also l... according to an Italian study that included 195 c...rticipants -- all with a sibling no more than four...ether they bullied or were bullied at school or at...
(Date:12/3/2009)...Finding could aid in eventual development of scree...DAY, Dec. 3 (HealthDay News) -- New research point...amin D and heart disease. , People with high bl...itamin D activation in the body were found to be t...e congestive heart failure, the study found. , ...
Breaking Medicine News(10 mins):Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:VIDEO from Medialink and the American Nurses Association (ANA): American Nurses Association Urges All Americans to Take Part in Health Care Reform Debate 2Health News:Bullies May Intimidate Siblings, Too 2Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2
...anizations are turning to Amalga to connect hospit...h centers., REDMOND, Wash., June 24 To improve t...to medically underserved,D.C. residents, the Distr... hospitals and six community-based health,centers ...
...COUVER, June 24 /PRNewswire-FirstCall/ - Beeston E...BB: BESE) announces that it completed,drilling on ... from,Candorado Operating Company Ltd. (TSX Ventur... copper-gold deposits., The Company is carrying o...
...New evidence-based guidelines address the preventi...ulations and reinforce recommendations related to ... as a supplement in the June issue of CHEST , the...ice Guidelines, Eighth Edition was developed by an...
...cuity,s Release of PriceAdvisor Combats Ineffectiv...action & Improve Revenue Projection and Recovery ...HILLS, Ill. and DUBLIN, Ireland, June 24 /PRNewswi...ology ("Peer,Reviewed by HFMA") and services, toda...
...tery shoppers allow providers to compare real expe...pectations., DALLAS, June 24 Mystery shopping go... why patients leave -- sometimes without,ever meet...come patients because they dismiss a healthcare or...
...3M Health Care today announced the launch of the 3...cal mask to meet the needs of clinicians seeking a...urgical mask incorporates proprietary filtration m... design, the 3M Filtron 1900 surgical mask provide...
Other Medicine News:Health News:District of Columbia Primary Care Association Selects Microsoft Amalga to Improve Patient Care for the Underserved 2Health News:District of Columbia Primary Care Association Selects Microsoft Amalga to Improve Patient Care for the Underserved 3Health News:Beeston completes drilling on Bluff Lake property, 100 Mile House 2Health News:New blood clot guidelines for pregnant women 2Health News:New blood clot guidelines for pregnant women 3Health News:New blood clot guidelines for pregnant women 4Health News:Concuity Announces the Availability of PriceAdvisor 2Health News:Concuity Announces the Availability of PriceAdvisor 3Health News:Concuity Announces the Availability of PriceAdvisor 4Health News:New White Paper from The Beryl Institute: 'Mystery Shopping the Patient Experience' 2Health News:3M Health Care launches new high-performance surgical mask 2
(Date:12/3/2009)... Dec. 3 ParagonRx, a Delaware-base...gement and optimal medication use, will host a fre... guidance on REMS - Risk Evaluation Mitigation Str...ecycle management. Dr. Gary Slatko, chief medical...sk management programs, will lead the one-hour pro...
(Date:12/3/2009)... Cardium Therapeutics (NY...ned subsidiary, Tissue Repair Company, submitted a.... Food and Drug Administration (FDA) seeking marke...didate based on positive data from the Company,s r... Today,s submission with the FDA covers Excellagen...
(Date:12/3/2009)...lif., Dec. 3 Each year, ... United States (U.S.) and Europe participate in th...ry experience under renowned faculty members at th...holars - past, present and future - will have excl...y at www.amgenscholars.com . ,, "The new Web ...
Breaking Medicine Technology:Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 2New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 1Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 11Maternal HIV 1 treatment protects against transmission to newborns 59640 1Maternal HIV 1 treatment protects against transmission to newborns 59640 2University of the Basque Country study on proteins related to Alzheimers 10397 1University of the Basque Country study on proteins related to Alzheimers 10397 2
...LES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corpora...gaged in the,development and commercialization of ... from the six-month, open-label extension,of its c... in ALS,volunteers. While the clinical trial was n...e three times daily appeared to be safe,and well-t...
...e Netherlands, June 27, 2007-Organon, the human,he...day that two,out of three Phase III clinical trial...g-acting fertility hormone, have reached,their ran...ew recombinant fertility hormone. It is,the first ...cular,stimulant or SFS) of which, due to its long ...
Other Medicine Technology:CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 2CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 3CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 5Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
Medium Clip Appliers
Li Brand™ Surgical Hemostat
The 2201
No Scalpel Vasectomy Hemostat
Medicine Products: